Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma

Journal of Extracellular Vesicles

Volumn 4, Issue 2015, 2015, Pages 1-10

  Jakobsen, Kristine R ^a,b   Paulsen, Birgitte S ^a   Bæk, Rikke ^c   Varming, Kim ^c   Sorensen, Boe S ^a   Jørgensen, Malene M ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

EV array; Exosomes; Extracellular vesicles; Lung cancer; NSCLC; Phenotyping; Plasma; Protein microarray

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD14 ANTIGEN; CD146 ANTIGEN; CD151 ANTIGEN; CD163 ANTIGEN; CD63 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPITHELIAL CELL ADHESION MOLECULE; FLOTILLIN 1; HEAT SHOCK PROTEIN 90; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MICROSOMAL AMINOPEPTIDASE; MUCIN 1; MUCIN 16; NERVE CELL ADHESION MOLECULE; PROTEIN P53; PROTEIN PLAP; PROTEIN TAG72; SCATTER FACTOR RECEPTOR; SURFACTANT PROTEIN D; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; EXTRACELLULAR VESICLE ARRAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

EID: 85016462671     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.3402/jev.v4.26659     Document Type: Article

References (65)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. American Cancer Society. Cancer facts and figures 2014 [Internet]. 2014 [cited 2014 Sep 22]. Available from: http://www. cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf
3. Engholm G, Ferlay J, Christensen N, Kejs AMT, Johannesen TB, Khan S, et al. 2011. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 6.0. Association of the Nordic Cancer Registries. Danish Cancer Society. [cited 2014 Sep 22]. Available from: http://www.ancr.nu
4. Provencio M, Isla D, Sánchez A, Cantos B. Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine. J Thorac Dis. 2011;3:197-204.
5. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985;101:942-8.
6. Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan J, et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget. 2014;5:7328-41.
7. Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166:7309-18.
8. Caby M-P, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int Immunol. 2005;17:879-87.
9. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10:42-6.
10. Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4:e5219.
11. Hong C-S, Muller L, Whiteside TL, Boyiadzis M. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol. 2014;5:160.
12. Huang S-H, Li Y, Zhang J, Rong J, Ye S. Epidermal growth factor receptor-containing exosomes induce tumour-specific regulatory T cells. Cancer Invest. 2013;31:330-5.
13. Ueda K, Ishikawa N, Tatsuguchi A, Saichi N, Fujii R, Nakagawa H. Antibody-coupled monolithic silica microtips for high throughput molecular profiling of circulating exosomes. Sci Rep. 2014;4:6232.
14. Melton L. Protein arrays: proteomics in multiplex. Nature. 2004;429:101-7, doi: http://dx.doi.org/10.1038/429101a
15. Jørgensen M, Bæk R, Pedersen S, Søndergaard EKL, Kristensen SR, Varming K. Extracellular vesicle (EV) Array: microarray capturing of exosomes and other extracellular vesicles for multiplexed phenotyping. J Extracell Vesicles. 2013;2:1-9.
16. Rødgaard-Hansen S, Rafique A, Christensen PA, Maniecki MB, Sandahl TD, Nexø E, et al. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin Chem Lab Med. 2014;52:453-61.
17. Kazankov K, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014;60:521-30.
18. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2:569-79, doi: http://dx.doi.org/10.1038/nri855
19. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic. 2002;3:321-30, doi: http://doi.wiley.com/10.1034/j.1600-0854.2002.30502.x
20. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008;68:5827-38.
21. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med. 2013;91:431-7.
22. Wick MR, Swanson PE, Manivel JC. Placental-like alkaline phosphatase reactivity in human tumors: an immunohistochemical study of 520 cases. Hum Pathol. 1987;18:946-54.
23. Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 2007;251:247-57.
24. Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM. Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. Bull Cancer. 1992;79:271-7.
25. Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013;108:662-7.
26. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010;70:1668-78.
27. Grah JJ, Katalinic D, Juretic A, Santek F, Samarzija M. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGEA3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori. 2014;100:60-8.
28. Sun N, Chen Z, Tan F, Zhang B, Yao R, Zhou C, et al. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. Clin Cancer Res. 2013;19:5136-45.
29. Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A. Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer. 1990;62:676-8.
30. Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol. 2008;39:126-36.
31. Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol. 2006;1:46-51.
32. Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z, et al. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res. 2014;34:3205-10.
33. Liu H, Gu X, Lv T, Wu Y, Xiao Y, Yuan D, et al. The role of serum carcinoembryonic antigen in predicting responses to chemotherapy and survival in patients with non-small cell lung cancer. J Cancer Res Ther. 2014;10:239-43.
34. Zhang P-F, Zeng G-Q, Hu R, Li C, Yi H, Li M-Y, et al. Identification of flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis. J Proteomics. 2012;77:202-14.
35. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol. 2006;37:1000-8.
36. Tokuhara T, Hasegawa H, Hattori N, Ishida H, Taki T, Tachibana S, et al. Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res. 2001;7:4109-14.
37. Kwon MJ, Seo J, Kim YJ, Kwon MJ, Choi JY, Kim T-E, et al. Prognostic significance of CD151 overexpression in non-small cell lung cancer. Lung Cancer. 2013;81:109-16.
38. Goldin-Lang P, Tran Q-V, Fichtner I, Eisenreich A, Antoniak S, Schulze K, et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumour metastasis. Oncol Rep. 2008;20:123-8.
39. Oka S, Uramoto H, Chikaishi Y, Tanaka F. The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung. Anticancer Res. 2012;32:861-4.
40. Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol. 2003;25:77-81.
41. Weber B, Hager H, Sorensen BS, McCulloch T, Mellemgaard A, Khalil AA, et al. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer. 2014;83:224-30.
42. Ise N, Omi K, Nambara D, Higashiyama S, Goishi K. Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors. Anticancer Res. 2011;31:4155-61.
43. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-smallcell lung cancer. Oncogene. 2009;28:S32-7.
44. Nielsen TO, Poulsen SS, Journe F, Ghanem G, Sorensen BS. HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma. Melanoma Res. 2014;24:88-91.
45. Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva G, Kremers G-J, et al. Amphiregulin exosomes increase cancer cell invasion. Curr Biol. 2011;21:779-86.
46. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107-16, doi:http://dx.doi.org/10.1038/labinvest.2013.130
47. Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther. 2014;96:214-23, doi:http://dx.doi.org/10.1038/clpt.2014.74
48. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415-23.
49. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007;98:1006-13.
50. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N, et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004;64:5283-90.
51. Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS One. 2013;8:e62171.
52. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 1995;13:1893-903.
53. Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M. Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:8674-9.
54. Del Vecchio CA, Giacomini CP, Vogel H, Jensen KC, Florio T, Merlo A, et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene. 2012;32:1-12.
55. Maniecki MB, Etzerodt A, Ulhøi BP, Steiniche T, Borre M, Dyrskjøt L, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012;131:2320-31.
56. Huang A, Zhang B, Wang B, Zhang F, Fan K-X, Guo Y-J. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013;62:1439-51.
57. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol. 2005;42:279-87.
58. Zhang J, Hawari FI, Shamburek RD, Adamik B, Kaler M, Islam A, et al. Circulating TNFR1 exosome-like vesicles partition with the LDL fraction of human plasma. Biochem Biophys Res Commun. 2008;366:579-84.
59. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012;23:507-15.
60. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-7.
61. Peinado H, AleČković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883-91.
62. Bobrie A, Théry C. Exosomes and communication between tumours and the immune system: are all exosomes equal? Biochem Soc Trans. 2013;41:263-7.
63. He M, Crow J, Roth M, Zeng Y, Godwin AK. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip. 2014;14:3773-80.
64. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep. 2007;17:319-23.
65. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 2003;94:50-6.